De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Dynavax Technologies Beheer
Beheer criteriumcontroles 4/4
De CEO Dynavax Technologies' is Ryan Spencer, benoemd in Dec2019, heeft een ambtstermijn van 4.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.81M, bestaande uit 13.1% salaris en 86.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde $ 2.56M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 6.3 jaar.
Belangrijke informatie
Ryan Spencer
Algemeen directeur
US$5.8m
Totale compensatie
| Percentage CEO-salaris | 13.1% |
| Dienstverband CEO | 4.8yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 6.3yrs |
Recente managementupdates
Recent updates
Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Dynavax: A Coronavirus Growth Story
Jan 17Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 18The Momentum Investor: Spotlight On Dynavax Technologies
Oct 25Dynavax And TLR Biology: Long-Delayed But Outstanding Success
Oct 16These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well
Oct 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$17m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$6m | US$760k | -US$6m |
| Sep 30 2023 | n/a | n/a | US$61m |
| Jun 30 2023 | n/a | n/a | US$111m |
| Mar 31 2023 | n/a | n/a | US$236m |
| Dec 31 2022 | US$6m | US$695k | US$293m |
| Sep 30 2022 | n/a | n/a | US$320m |
| Jun 30 2022 | n/a | n/a | US$228m |
| Mar 31 2022 | n/a | n/a | US$104m |
| Dec 31 2021 | US$5m | US$600k | US$72m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$2m | US$515k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$97m |
| Jun 30 2020 | n/a | n/a | -US$138m |
| Mar 31 2020 | n/a | n/a | -US$129m |
| Dec 31 2019 | US$3m | US$391k | -US$156m |
Compensatie versus markt: De totale vergoeding ($USD 5.81M ) Ryan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).
Compensatie versus inkomsten: De vergoeding van Ryan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Ryan Spencer (46 yo)
4.8yrs
Tenure
US$5,810,736
Compensatie
Mr. Ryan Spencer serves as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as the Chief Executive Officer and Director of Dynavax Technologies Corporation since December 16...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$5.81m | 0.18% $ 2.6m | |
| President & COO | 11.6yrs | US$2.99m | 0.024% $ 360.9k | |
| Senior VP & CFO | 3.6yrs | US$2.07m | 0.0059% $ 86.9k | |
| Chief Medical Officer and Senior VP of Clinical Development | 11.3yrs | US$1.88m | 0.049% $ 726.2k | |
| Chief Accounting Officer & Controller | 4.4yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Human Resources Officer | 5.8yrs | geen gegevens | geen gegevens | |
| VP of Investor Relations & Corporate Communications | 1.8yrs | geen gegevens | geen gegevens | |
| Senior VP & General Counsel | 3.3yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Commercial Officer | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Vaccine Research | 3.7yrs | geen gegevens | geen gegevens | |
| VP, Site Head & MD for Dynavax GmbH | 3.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Technical Operations | 3.8yrs | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
59.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DVAX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$5.81m | 0.18% $ 2.6m | |
| Independent Director | 18.2yrs | US$298.73k | 0.021% $ 313.3k | |
| Independent Director | 14.3yrs | US$290.73k | 0.0011% $ 16.9k | |
| Independent Director | 14.9yrs | US$278.73k | 0.016% $ 235.4k | |
| Member of Scientific Advisory Board | 1.8yrs | US$1.83m | geen gegevens | |
| Member of Scientific Advisory Board | 6.3yrs | geen gegevens | geen gegevens | |
| Independent Director | 4.3yrs | US$293.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.3yrs | US$20.00k | geen gegevens | |
| Independent Chairman of the Board | 3yrs | US$323.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 6.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 6.3yrs | geen gegevens | geen gegevens |
6.3yrs
Gemiddelde duur
73.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DVAX wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).